Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment
Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...
SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial
SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in ...
manilatimes2d
Greenheart Gold Has Entered Into an Option Agreement to Acquire a 100% Interest in the Tosso Creek Exploration Project in Suriname
The 96-square-kilometer Tosso Creek Project is located in southern Suriname, approximately 180 km south of the capital city, ...
Sellas Life Sciences’ zanubrutinib combination shows efficacy in DLBCL
Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in ...
SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall ...
BioSpace24d
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to ...
Nasdaq24d
SELLAS Life Sciences Group, Inc. Secures $25 Million in Registered Direct Offering for Cancer Therapeutics Development
SELLAS focuses on developing innovative cancer therapies, including their lead candidate GPS, which targets the WT1 protein, and SLS009, a small molecule CDK9 inhibitor. SELLAS Life Sciences has ...
Morningstar24d
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared ...